Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis.
Efficacy
Meta-analysis
Ruxolitinib
Safety
Systematic review
Journal
Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575
Informations de publication
Date de publication:
02 Oct 2024
02 Oct 2024
Historique:
received:
14
07
2023
accepted:
02
09
2024
medline:
3
10
2024
pubmed:
3
10
2024
entrez:
2
10
2024
Statut:
epublish
Résumé
Vitiligo is a chronic skin disorder causing depigmentation. There is a lack of evidence-based medical evidence regarding ruxolitinib efficacy and safety for vitiligo. To assess the efficacy and safety of ruxolitinib cream in the treatment of vitiligo. The databases of PubMed, Embase, and Cochrane Library were searched. The literature screening was independently conducted by two reviewers. For continuous variables, weighted mean difference (WMD) along with a 95% confidence interval (CI) was performed. For dichotomous outcomes, we calculated the odds ratios (ORs) or risk ratios (RRs), and their corresponding 95% CIs. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE). Symptoms, quality of life, and safety were evaluated using various measures, including the Facial Vitiligo Area Scoring Index (F-VASI), Total Vitiligo Area Scoring Index (T-VASI), Facial Body Surface Area (F-BAS), Total Body Surface Area (T-BAS) and Treatment-emergent Adverse Events (TEAEs). Three trials, involving a total of 830 participants from nine countries were included (female 388, 46.7%, male 442, 53.3%). The meta-analysis demonstrated a significant increase in the likelihood of participants achieving F-VASI75 (OR, 4.34 [95% CI 2.67-7.06]; high), F-VASI50 (OR 4.71 [95% CI 3.24-6.84]; high), T-VASI75 (OR 2.78 [95% CI 1.10-7.00]; moderate), and T-VASI50 (OR 4.47 [95% CI 2.52-7.92]; high) when compared ruxolitinib to vehicle. Ruxolitinib was associated with more lowered percentage change of F-VASI scores (MD - 32.79 [95% CI - 36.37 to - 29.21]; moderate), and T-VASI scores (MD - 20.22 [95% CI - 23.11 to - 17.33]; moderate) from baseline compared to vehicle. There may not be a significant difference in the occurrence of TEAEs between ruxolitinib and vehicle (RR 1.46 [95% CI 0.85-2.49]; high). The findings suggest that ruxolitinib cream holds promise as a treatment option for vitiligo. Further long-term studies are needed to assess its sustained efficacy and safety profile. PROSPERO CRD42023431112.
Identifiants
pubmed: 39358803
doi: 10.1186/s13643-024-02653-7
pii: 10.1186/s13643-024-02653-7
doi:
Substances chimiques
ruxolitinib
82S8X8XX8H
Pyrimidines
0
Pyrazoles
0
Nitriles
0
Types de publication
Systematic Review
Journal Article
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
250Informations de copyright
© 2024. The Author(s).
Références
Ezzedine K, Eleftheriadou V, Whitton M, et al. Vitiligo Lancet. 2015;386(9988):74–84.
doi: 10.1016/S0140-6736(14)60763-7
pubmed: 25596811
Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236(6):571–92.
doi: 10.1159/000506103
pubmed: 32155629
Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206–12.
doi: 10.1111/j.1365-4632.2011.05377.x
pubmed: 22458952
Alikhan A, Felsten LM, Daly M, et al. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–491.
Zhang Y, Cai Y, Shi M, et al. The Prevalence of Vitiligo: A Meta-Analysis. PLoS ONE. 2016;11(9): e0163806.
doi: 10.1371/journal.pone.0163806
pubmed: 27673680
pmcid: 5038943
Sehgal VN, Srivastava G. Vitiligo: compendium of clinico-epidemiological features. Indian J Dermatol Venereol Leprol. 2007;73(3):149–56.
doi: 10.4103/0378-6323.32708
pubmed: 17558045
Elbuluk N, Ezzedine K. Quality of Life, Burden of Disease, Co-morbidities, and Systemic Effects in Vitiligo Patients. Dermatol Clin. 2017;35(2):117–128. Bibeau K, Pandya AG, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022;36(10):1831–1844.
Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90–100.
doi: 10.1034/j.1600-0749.2003.00023.x
pubmed: 12622785
Qi F, Liu F, Gao L. Janus Kinase Inhibitors in the Treatment of Vitiligo: A Review. Front Immunol. 2021;12: 790125.
doi: 10.3389/fimmu.2021.790125
pubmed: 34868078
pmcid: 8636851
Rosmarin D, Passeron T, Pandya AG, et al. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022;387(16):1445–55.
doi: 10.1056/NEJMoa2118828
pubmed: 36260792
Rosmarin D, Pandya AG, Lebwohl M, et al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110–20.
doi: 10.1016/S0140-6736(20)30609-7
pubmed: 32653055
Joshipura D, Alomran A, Zancanaro P, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open-label extension study with optional narrow-band ultraviolet B. J Am Acad Dermatol. 78(6):1205–1207.e1.
Gao Y, Yang K, Cai Y, et al. Updating systematic reviews can improve the precision of outcomes: a comparative study. J Clin Epidemiol. 2020;125:108–19.
doi: 10.1016/j.jclinepi.2020.05.019
pubmed: 32442481
Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook .
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.
doi: 10.1136/bmj.n71
pubmed: 33782057
pmcid: 8005924
Guyatt GH, Busse JW. Modification of Cochrane tool to assess risk of bias in randomized trials. https://www.evidencepartners.com/resources/methodological-resources/ .
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6.
doi: 10.1136/bmj.39489.470347.AD
pubmed: 18436948
pmcid: 2335261
Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol. 2011;64(4): 407–415.
Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011;64(12): 1283–1293.
Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence--inconsistency. J Clin Epidemiol. 2011;64(12): 1294–1302.
Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence--indirectness. J Clin Epidemiol. 2011;64(12): 1303–1310.
Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5. Rating the quality of evidence--publication bias. J Clin Epidemiol. 2011;64(12): 1277–1282.
Picardo M, Dell’Anna ML, Ezzedine K, et al. Vitiligo Nat Rev Dis Primers. 2015;1:15011.
doi: 10.1038/nrdp.2015.11
pubmed: 27189851
Shin S, Shin JY, Lee H, et al. Spreading of pre-existing segmental vitiligo after immunotherapy with house dust mite in a patient with atopic dermatitis. Clin Exp Dermatol. 2015;40(8):920–1.
doi: 10.1111/ced.12443
pubmed: 25252044
Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. Br J Dermatol. 2022;186(1):18–29.
doi: 10.1111/bjd.20596
pubmed: 34160061
Speeckaert R, van Geel N. Vitiligo: An Update on Pathophysiology and Treatment Options. Am J Clin Dermatol. 2017;18(6):733–44.
doi: 10.1007/s40257-017-0298-5
pubmed: 28577207
Cunningham KN, Rosmarin D. Vitiligo Treatments: Review of Current Therapeutic Modalities and JAK Inhibitors. Am J Clin Dermatol. 2023;24(2):165–86.
doi: 10.1007/s40257-022-00752-6
pubmed: 36715849
Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149(2):159–64.
doi: 10.1001/jamadermatol.2013.927
pubmed: 23560296
Wong SM, Baba R. Quality of life among Malaysian patients with vitiligo. Int J Dermatol. 2012;51(2):158–61.
doi: 10.1111/j.1365-4632.2011.04932.x
pubmed: 22250623
Morrison B, Burden-Teh E, Batchelor JM, et al. Quality of life in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2017;177(6):e338–9.
doi: 10.1111/bjd.15933
pubmed: 28869779
Hwang JR, Driscoll MS. Review of Ruxolitinib for Treatment of Non-Segmental Vitiligo. Ann Pharmacother. 2022: 10600280221143748.
Tavoletti G, Avallone G, Conforti C, et al. Topical ruxolitinib: A new treatment for vitiligo. J Eur Acad Dermatol Venereol. 2023; 0: 1–9.
Smith P, Yao W, Shepard S, et al. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream. Pharmaceutics. 2021;13(7):1044.
doi: 10.3390/pharmaceutics13071044
pubmed: 34371735
pmcid: 8309120